Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 5/20 | 0.47 |
| ▸ | FABP3 | P05413 | 4/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489488 | 0.83 | FABP4 (0.51) | FABP4FABP3FABP5CHEK1CCNE1 | |
| SCHEMBL3828856 | 0.83 | FABP4 (0.56) | FABP4FABP3FABP5CHEK1CCNE1 | |
| SCHEMBL4481685 | 0.78 | NPC1 (0.55) | FABP4FABP3FABP5CHEK1KDM4E | |
| SCHEMBL13674672 | 0.71 | PLA2G10 (0.48) | FABP4FABP3FABP5CHEK1PLA2G10 | |
| SCHEMBL3825249 | 0.71 | PLA2G10 (0.43) | FABP4FABP3FABP5CHEK1CCNE1 | |
| SCHEMBL13675489 | 0.68 | PLA2G10 (0.43) | FABP4FABP3CHEK1PLA2G10ERN1 | |
| SCHEMBL13990290 | 0.65 | DYRK1A (0.51) | CHEK1PLA2G10ERN1KDM4EALDH1A1 | |
| SCHEMBL30398484 | 0.64 | FABP4 (1.00) | FABP4FABP3FABP5 | |
| SCHEMBL976455 | 0.64 | CDC7 (0.57) | CHEK1CCNE1CDK2PLA2G10KDM4E | |
| SCHEMBL28563503 | 0.64 | FABP4 (1.00) | FABP4FABP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270456-A1 | Novel chemical compounds | HASEGAWA MASAICHI | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270456-A1 | Novel chemical compounds | HIPK3, HIPK2, HIPK1 | FABP4 3496/4885FABP3 796/4885FABP5 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.